Nuvation Bio (NUVB) Receivables - Other (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Receivables - Other of $3.3 million for Q1 2026, down 35.46% year-over-year from $5.1 million in Q1 2025, and down 0.73% quarter-over-quarter from $3.3 million in Q4 2025.
Nuvation Bio (NUVB) Receivables - Other (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Receivables - Other for 7 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Other fell 35.46% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (down 35.46% YoY), while the FY2025 annual figure was $3.3 million, down 7.98% from the prior year.
- Receivables - Other retreated to $3.3 million in Q1 2026 per NUVB's latest filing, from $3.3 million in the prior quarter.
- Across five years, Receivables - Other topped out at $5.5 million in Q3 2025 and bottomed at $2.3 million in Q1 2023.
- Historically, Receivables - Other has averaged $3.5 million across 5 years, with a median of $3.3 million in 2025.
- Annual changes were most pronounced in 2022 — Receivables - Other surged 145.62% — and 2026, when it sank 35.46%.
- Nuvation Bio's Receivables - Other stood at $2.5 million in 2022, then jumped by 48.97% to $3.7 million in 2023, then slipped by 3.57% to $3.6 million in 2024, then retreated by 7.98% to $3.3 million in 2025, then decreased by 0.73% to $3.3 million in 2026.
- Business Quant data shows NUVB's Receivables - Other at $3.3 million in Q1 2026, $3.3 million in Q4 2025, and $5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.89 Mn |
| Jun 30, 2026 | 3.89 Mn |
| Mar 31, 2026 | 3.26 Mn |
| Mar 31, 2026 | 3.26 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Sep 30, 2025 | 5.53 Mn |
| Sep 30, 2025 | 5.53 Mn |
| Jun 30, 2025 | 3.98 Mn |
| Jun 30, 2025 | 3.98 Mn |
| Mar 31, 2025 | 5.05 Mn |
| Mar 31, 2025 | 5.05 Mn |
| Dec 31, 2024 | 3.57 Mn |
| Dec 31, 2024 | 3.57 Mn |
| Sep 30, 2024 | 4.14 Mn |
| Sep 30, 2024 | 4.14 Mn |
| Jun 30, 2024 | 3.90 Mn |
| Jun 30, 2024 | 3.90 Mn |
| Mar 31, 2024 | 4.28 Mn |
| Mar 31, 2024 | 4.28 Mn |